Efficacy of Veklury® (remdesivir) against new SARS-CoV-2 variants
Efficacy of Veklury® (remdesivir) against new SARS-CoV-2 variants
“Remdesivir exhibits potent in vitro antiviral activity against SARS-CoV-2 and is currently the only antiviral drug licensed for the treatment of COVID-19. We have completed genetic analysis of publicly available sequences for the UK and SA variants of SARS-CoV-2 and we believe remdesivir will continue to be effective against these variants. The mutations identified in these new variants have not significantly altered the part of the virus that remdesivir targets or have any association with known mutations conferring reduced susceptibility of coronaviruses to remdesivir in vitro. We continue to conduct additional research to evaluate newly emerging variants and to further understand their potential impact on remdesivir.”
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
